czilk dc inc

2025-01-10 2025 European Cup czilk dc inc News

czilk dc inc Global Outage Strikes Meta Platforms, Afflicting Facebook, Instagram, and WhatsApp Services

None'Wicked' and 'Gladiator' make gravity-defying theater debuts NEW YORK (AP) — “Wicked” and “Gladiator II” have debuted in theaters with a combined $270 million in ticket sales. Their worldwide performance breathed fresh life into global box office results that have struggled lately. Together the films turned the moviegoing weekend into one of the busiest of the year. Jon M. Chu’s lavish big-budget musical “Wicked,” starring Ariana Grande and Cynthia Erivo, debuted with $114 million domestically and $164.2 million globally. Ridley Scott’s “Gladiator II” is a sequel to his 2000 best picture-winning original and launched with $55.5 million in ticket sales. “Moana 2” is being released Wednesday, so it looks like Hollywood might be looking at historic sales over the Thanksgiving holiday. Verstappen captures 4th F1 championship after Mercedes sweep of Las Vegas Grand Prix LAS VEGAS (AP) — Max Verstappen cruised to a fourth consecutive Formula 1 championship Saturday night by finishing fifth in the Las Vegas Grand Prix. Verstappen needed only to finish ahead of Lando Norris of McLaren to give Red Bull a fourth straight driver championship. The Dutchman started fifth but was already up to second by the 10th lap around the street circuit that includes the famed Las Vegas Strip. Norris, who had to score at least three points more than Verstappen to extend the championship fight, finished sixth. The race was won by George Russell who was followed by Lewis Hamilton in the first 1-2 sweep for the Mercedes drivers since 2022. Dartmouth sorority, two members of fraternity face charges after student who attended party drowned HANOVER, N.H. (AP) — A sorority at Dartmouth College and two members of a fraternity faces charges related to the death of a student who drowned after attending an off-campus party. The Hanover, New Hampshire police department, where Dartmouth is located, said Friday that Alpha Phi was charged with one count of facilitating an underage alcohol house. Two members of the Beta Alpha Omega face a charge of providing alcohol to a person under 21. Won Jang, 20, of Middletown, Delaware, had attended an off-campus party in July hosted by Alpha Phi sorority. Police said the alcohol was provided by Beta Alpha Omega. Tens of thousands of Spaniards protest housing crunch and high rents in Barcelona BARCELONA, Spain (AP) — Tens of thousands of Spaniards are marching in downtown Barcelona to protest the skyrocketing cost of renting an apartment in the popular tourist destination. Protesters cut off traffic on main avenues in the city center, holding up homemade signs in Spanish reading “Fewer apartments for investing and more homes for living." The lack of affordable housing has become one of the leading concerns for the southern European Union country, mirroring the housing crunch across many parts of the world, including the United States. The average rent for Spain has doubled in the last decade. In cities like Barcelona, rental prices have also been driven up by short-term renters including tourists. Jason Kelce's wife announces she is pregnant with the couple's fourth child Former Philadelphia Eagles center Jason Kelce's wife is announcing she's pregnant with the couple's fourth child. Kylie Kelce posted a photo on Instagram on Friday of the couple's three young daughters reacting to the news. The oldest daughter, Wyatt, appears to be cupping her head in shock. The middle daughter, Ellioette, is smiling. The youngest, Bennett, is in tears. A caption attached to the photo reads: “I feel like we captured a very accurate representation of how each of the girls feel about getting another sister. At least Ellie, mom and dad are on the same page!” Israeli-Moldovan rabbi living in UAE is missing. Israeli officials fear he may have been kidnapped DUBAI, United Arab Emirates (AP) — An Israeli-Moldovan rabbi living in the United Arab Emirates has gone missing, with Israeli authorities raising the suspicion he may have been kidnapped as tensions remain high with Iran. The Israeli prime minister’s office said that Zvi Kogan has been missing since noon Thursday. It said that against the backdrop of information that this was a terrorist incident, an extensive investigation has been opened in the country. Emirati officials did not immediately respond to a request for comment Saturday. State-run media in the UAE, an autocratic federation of seven sheikhdoms on the Arabian Peninsula and home to Abu Dhabi and Dubai, did not immediately report the incident. Alyssa Nakken, first full-time female coach in MLB history, leaving Giants to join Guardians CLEVELAND (AP) — Alyssa Nakken, the first woman to coach in an MLB game, is leaving the San Francisco Giants to join the Cleveland Guardians. Nakken made history in 2022 when she took over as first-base coach following an ejection. A former college softball star at Sacramento State, Nakken joined the Giants in 2014 and was promoted to a spot on manager Gabe Kapler’s staff in 2020, becoming the majors’ first full-time female coach. Nakken has been hired as an assistant director within player development for the Guardians, who won the AL Central last season under first-year manager Stephen Vogt. Nakken, 34, will work with former Giants coaches Craig Albernaz and Kai Correa. Officer kills pet dog mistaken for a coyote in Massachusetts town. The owner says it was unnecessary An animal control officer shot and killed a pet dog in a Massachusetts town after mistaking it for a coyote in an incident local police are describing as a sad mix-up. Police in Northbridge, Massachusetts, say the shooting happened on Tuesday after police received a call of a report of a coyote in a residential backyard. Police say the animal control officer went into the woods to look for the coyote and found what they thought was the animal in a threatening position and shot it. The incident happened as communities around Massachusetts and the country have dealt with an uptick in interactions between coyotes and people. Kendrick Lamar surprises with new album 'GNX' LOS ANGELES (AP) — Kendrick Lamar gave music listeners an early holiday present with a new album. The Grammy winner released his sixth studio album “GNX” on Friday. The 12-track project is the rapper’s first release since 2022’s “Mr. Morale & The Big Steppers.” Lamar’s new album comes just months after his rap battle with Drake. The rap megastar will headline February's Apple Music Super Bowl Halftime Show in New Orleans. The 37-year-old has experienced massive success since his debut album “good kid, m.A.A.d city” in 2012. Since then, he’s accumulated 17 Grammy wins and became the first non-classical, non-jazz musician to win a Pulitzer Prize. NBA memo to players urges increased vigilance regarding home security following break-ins MIAMI (AP) — The NBA is urging its players to take additional precautions to secure their homes following reports of recent high-profile burglaries of dwellings owned by Milwaukee Bucks forward Bobby Portis and Kansas City Chiefs teammates Patrick Mahomes and Travis Kelce. In a memo sent to team officials, a copy of which was obtained by The Associated Press, the NBA revealed that the FBI has connected some burglaries to “transnational South American Theft Groups” that are “reportedly well-organized, sophisticated rings that incorporate advanced techniques and technologies, including pre-surveillance, drones, and signal jamming devices.”As baseball staffers, agents and media members alike started to congregate around the hotel's central bar, the conversation, predictably, was dominated by Soto. A narrative soon took hold: Cohen was holding up a proverbial middle finger to the Yankees.Qatar tribune Agencies The European Union and South America’s Mercosur trade bloc on Friday agreed to terms for a long-anticipated free trade deal, which now, however, faces a tortuous battle for approval in Europe, where there is stiff opposition from France. After negotiations spanning over 20 years, and five years on from an initial deal, European Commission President Ursula von der Leyen and her Mercosur counterparts announced an agreement had been reached in the Uruguayan capital Montevideo. The deal aims to create one of the largest free trade zones in the world, covering over 700 million people and nearly 25% of global gross domestic product (GDP). Much like the U.S.-Mexico-Canada free trade agreement, its goal is to reduce tariffs and trade barriers, making it easier for businesses on both sides to export goods. Mercosur comprises Brazil – the lion’s share of the bloc’s territory, economic output and population – along with Argentina, Paraguay, Uruguay and Bolivia, the newest member. Venezuela’s membership has been suspended indefinitely. “This is a win-win agreement,” von der Leyen said in a press conference in Montevideo alongside the presidents of the Mercosur nations. “This agreement is not just an economic opportunity, it is a political necessity,” she added. “I know that strong winds are coming in the opposite direction, toward isolation and fragmentation, but this agreement is our near response.” The deal is not the end of the story for the Europeans. France leads a group of member countries who still have objections to the pact, and all 27 member countries must endorse it for the agreement to enter force. In remarks aimed at her “fellow Europeans,” and perhaps those more skeptical like farmers in France and elsewhere, von der Leyen said it would have a positive impact on around 60,000 companies that export to the Mercosur region. She said they will “benefit from reduced tariffs, simpler customs procedures and preferential access to some critical raw materials. This will create huge business opportunities.” “And to our farmers,” she said, “we have heard you listen to your concerns, and we are acting on them. This agreement includes robust safeguards to protect your livelihoods.” Reaching a deal has been a protracted process, dating back to a summit in Rio de Janeiro in 1999. Negotiations quickly stalled due to different economic priorities, tariffs, regulatory standards and agricultural policies on both sides of the Atlantic Ocean. For about a decade, the EU sought to protect its agricultural sector while Mercosur aimed to increase access to its agricultural products. Some momentum came after 2010, when both sides focused on eliminating tariffs, though issues for agriculture remained. The peak of that movement was a political agreement in June 2019, when negotiators announced a deal that included provisions for tariff reductions and commitments to environmental standards. Since then, the two sides have struggled to ratify a deal. European concerns over deforestation in the Amazon, particularly during the Jair Bolsonaro presidency in Brazil until the end of 2022, held up an agreement. Left-wing President Luiz Inacio Lula da Silva, Bolsonaro’s successor, initially opposed an agreement more than two decades ago. But since returning to power in 2023, his administration has pushed for progress. “After more than two decades, we have concluded negotiations on the agreement,” Lula wrote on social media platform X. The outgoing government of Argentina, the bloc’s second-biggest economy, opposed the agreement, but President Javier Milei, who took office last year, has supported a deal. France, the most vociferous critic of the deal, has branded it as “unacceptable.” Underscoring the obstacles it now faces, French Trade Minister Sophie Primas pledged to resist its next stages, citing environmental and farming concerns. Copy 09/12/2024 10

It’s a shame that the Celtics and Timberwolves play each other just twice per season. Lately, whenever Boston and Minnesota square off, drama ensues. Sunday’s matchup at TD Garden was no different, with the Celtics surviving a furious Wolves comeback to win 107-105. Jaylen Brown’s 3-pointer with 76 seconds remaining proved to be the difference, capping a 29-point performance that also included Boston’s first 15 points of the game. Naz Reid had a chance to win it for Minnesota as time expired, but his three both missed the mark and did not leave his hand before the final buzzer. Jayson Tatum added 26 points, eight rebounds, four assists and two steals for Boston, which won its fifth straight to improve to 14-3. Derrick White finished with 19 points, nine rebounds, five assists, two blocks and a steal. Brown, Tatum and White combined to shoot 16-for-31 (51.6%) from 3-point range in the win. Anthony Edwards and Julius Randle scored 28 and 23 points, respectively, to lead the Timberwolves, who have not won in Boston since 2005. Rudy Gobert grabbed 20 rebounds — the most by a Celtics opponent this season — including eight offensive boards. Brown got off to a scorching start for the Celtics, drilling five 3-pointers on five shots in the first 3:14 of game time. The NBA Finals MVP hadn’t hit five threes in any full game since Boston’s season opener, and he reached that mark just four times all last season. With Brown’s hand hot, head coach Joe Mazzulla deviated from his typical early-game plan, giving Tatum a rest after eight minutes and playing Brown for the entire first quarter. Those roles have been flipped in most games this season, with Tatum playing the full opening frame in all but one contest before Sunday. Brown’s 5-for-5 start represented nearly all of Boston’s first-quarter offense, however. The team made just three of its other 18 field goals, and it took more than nine minutes for any other Celtics player to record a point. Minnesota led 27-24 after one. Tatum, held scoreless in the first, fueled Boston in the second quarter with 13 points on seven shots, including a second-chance 3-pointer off a Sam Hauser offensive rebound and a tough driving layup over reigning NBA Defensive Player of the Year Gobert. Al Horford also sank two threes in the quarter as the Celtics built a 10-point lead. But the Wolves scored the final nine points of the half, routinely exploiting one of the Celtics’ biggest weaknesses so far this season: rim protection. Minnesota went 11-for-13 inside the restricted area in the first half (and 10-for-36 on all other shots) and trailed 55-52 at halftime. That interior success kept the Wolves competitive for a half. But the Celtics’ 3-point barrage eventually became too much for the underdog visitors to handle. Boston made six threes in the first 6 1/2 minutes of the third quarter — three by Tatum; one each by Brown, Horford and Jrue Holiday — to open up a 19-point lead. The Celtics also blocked five Timberwolves shots in the quarter, including two rejections by White. Another of those came courtesy of Xavier Tillman, who saw his largest workload in weeks as Mazzulla shook up his frontcourt rotation. With Luke Kornet (hamstring tightness) inactive, Mazzulla used Tillman as Horford’s top backup rather than the struggling Neemias Queta. Tillman played 14 minutes, finishing with three points, four rebounds and one block. Queta, who came in averaging 22.5 minutes per game in November, was a healthy DNP for the first time since Oct. 26. The Celtics carried an 84-73 lead into the fourth quarter, then had to fend off a late Timberwolves charge led by backup guard Rob Dillingham, who hit two threes and a layup to help Minnesota close the gap. Edwards added two threes of his own after checking back in for Dillingham, and Jaden McDaniels’ driving baseline dunk with 2:04 remaining cut Boston’s lead to 104-102. But Brown’s three on the ensuing Celtics possession proved to be the game-winner, though he missed another shortly thereafter that could have iced the game. A Randle layup got Minnesota within two, but Reid couldn’t convert his would-be buzzer-beater.

San Francisco 49ers quarterback Brock Purdy will miss Sunday's game against the Packers with a sore throwing shoulderBe more transparent with yours data billings – NCC tells network providers

Châtillon, France, December 11 th , 2024 DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old DBV and FDA aligned on key study design elements for the COMFORT Toddlers study in 1 – 3 year-olds, including study size and wear time collection methodology and analysis COMFORT Toddlers study on-track to initiate in 2Q 2025 Viaskin Peanut patch BLA submission for the Toddlers indication anticipated for 2H 2026 FDA confirmed criteria for post-marketing confirmatory study in toddlers 1 – 3 years-old Company to host investor webcast today at 5:00pm ET DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the successful outcome of recent written and oral communication with the U.S. Food and Drug Administration (FDA) that provides a clear and well-defined regulatory pathway for the Viaskin Peanut patch program in toddlers 1 – 3-years-old. The FDA has formalized guidance on an Accelerated Approval for the Viaskin Peanut patch in toddlers 1 – 3-years-old. DBV and FDA have agreed on the key design elements for a post-marketing confirmatory study. “DBV is pleased to have received, what we believe to be, a clear and reasonable pathway towards an Accelerated Approval for the Viaskin Peanut patch in toddlers 1 – 3-years-old. This comes on the heels of our October 22 nd press release announcing details in support of our separate Viaskin Peanut programs in 4 – 7 year-olds and in 1 – 7 year-olds in Europe,” said Daniel Tassé, Chief Executive Officer, DBV Technologies. “We believe we have decreased the regulatory pathway risk of our programs. DBV can now fully focus on executing the remaining studies that will support two distinct BLAs across age groups and an MAA in Europe. We are grateful to the Agency for its attentive collaboration as we continue to work towards introducing this novel therapy to caregivers and patients as expeditiously as possible.” Accelerated Approval Pathway The FDA recently issued written communication confirming an Accelerated Approval pathway for the Viaskin Peanut patch in toddlers 1 – 3-years-old. As a reminder, current FDA guidance for Accelerated Approval includes three qualifying criteria: That the product candidate treats a serious condition That the product candidate generally provides a meaningful advantage over available therapies That the product candidate demonstrates an effect or an intermediate clinical endpoint that is reasonably likely to predict clinical benefit As DBV previously announced , FDA confirmed via written communication that the Viaskin Peanut patch already met criteria one and two. FDA and DBV have been engaged in ongoing dialogue throughout Q4 of this year regarding the intermediate clinical endpoint necessary to meet the third criterion. In the recent written communication, the FDA confirmed the efficacy data from the Company’s Phase 3 EPITOPE study can serve as an intermediate clinical endpoint. The FDA has agreed that the endpoint is reasonably likely to predict clinical benefit and will therefore fulfill the requirement for Accelerated Approval. In preparation for commercialization, DBV made slight modifications to the Viaskin Peanut patch used in EPITOPE to increase the simplicity of application for the caregiver and provide product identification on each patch. No changes, including patch shape or size, were made to the device components that are in contact with the patient’s skin. Further, to increase the volume of patch production for future commercialization, changes needed to be made to the manufacturing process and location. Although the intended commercial Viaskin Peanut patch is currently being used (N=304) in the ongoing 3-year Open Label Extension to EPITOPE, the collective changes to the commercial Viaskin Peanut patch were viewed by the FDA as constituting a different product relative to the clinical patch used in the EPITOPE study. The Company intends to use the commercial Viaskin Peanut patch in both the COMFORT Toddlers study and the post-marketing confirmatory study. Post-Marketing Confirmatory Study In the recent written communication, FDA confirmed criteria for a post-marketing confirmatory study in toddlers 1 – 3-years-old. DBV and FDA agreed that the confirmatory study will assess the effectiveness of the intended commercial Viaskin Peanut patch and will need to be initiated at the time that the BLA is submitted. To date, the commercial patch has been used in 304 subjects with over 234,695 patient-days of therapy in the placebo crossover and the EPITOPE Open Label Extension, with no clinically relevant differences in efficacy or safety vs. the clinical patch used in the EPITOPE Phase 3 trial. The confirmatory study will include a double-blind, placebo-controlled food challenge (DBPCFC) and will use the same statistical criteria for success (i.e., lower bound of the 95% CI > 15%) as used in the EPITOPE Phase 3 efficacy study. Adhesion data for the post-marketing confirmatory study will be collected in a similar manner relative to the COMFORT Toddlers study. The Company expects these data will further support the importance of average daily wear time in the use of the Viaskin Peanut patch as it relates to efficacy and labeling. “When it comes to food allergy management, what works for one family, might not work for another. That is why having varied treatment options available is so incredibly important to our community,” said Sung Poblete, PhD, RN, CEO of FARE (Food Allergy Research & Education). “I’m pleased to learn that DBV’s constructive dialogue with the FDA has resulted in this Accelerated Approval guidance outlining remaining developmental steps for the Viaskin Peanut patch in toddlers with a peanut allergy. At FARE, we look forward to the possibility that one day, if approved, caregivers and families will have this exciting new treatment as an option to consider.” COMFORT Toddlers Supplemental Safety Study COMFORT Toddlers is a Phase 3 double-blind, placebo-controlled (DBPC) study designed to generate additional safety (primary endpoint) and adhesion data of the Viaskin Peanut patch in peanut allergic toddlers 1 – 3-years old. DBV is pleased to announce that Dr. Julie Wang, MD, Professor of Pediatrics, Jaffe Food Allergy Institute, the Icahn school of Medicine at Mount Sinai, will act as the Global Principal Investigator for the COMFORT Toddlers study. “I am thrilled to assume the role of Global Principal Investigator of the COMFORT Toddlers study,” stated Dr. Julie Wang, Professor of Pediatrics, Jaffe Food Allergy Institute, Icahn school of Medicine at Mount Sinai in New York. “Viaskin Peanut, if approved, would offer a much-needed alternative treatment option for patients and caregivers. I look forward to working with the DBV team to advance this important clinical trial.” The Company anticipates that COMFORT Toddlers will enroll approximately 480 subjects randomized 3:1 (active: placebo) at approximately 80 – 90 study centers across the U.S., Canada, Australia, and Europe. COMFORT Toddlers will be a six-month study followed by an optional 18-month open-label treatment phase, to provide 24 or 18 months of treatment with the Viaskin Peanut patch for participants randomized to the active or placebo groups, respectively. Thus, the COMFORT Toddlers study will increase the total subjects exposed to the Viaskin Peanut patch for at least six-months in a controlled study to 600, as required by FDA. In total, there will be approximately 240 subjects with the clinical patch in EPITOPE and 360 with the commercial patch in COMFORT Toddlers. As previously disclosed , DBV and FDA have aligned on a patch wear time collection methodology, analysis and study objective hierarchy in the COMFORT Toddlers study. The agreed-upon adhesion data collection methodology provides a practical approach for subjects, families, and investigators. The methodology is intended to generate sufficient data to support a BLA submission under the Accelerated Approval pathway (i.e., collecting patch adhesion data with a focus on daily wear time at relevant time points). We believe there are three positive outcomes coming out of the productive discussions with FDA: FDA agreed that adhesion would not be a co-objective of a safety study and would be an exploratory endpoint. Next, adhesion should be assessed in the overall totality of benefit to risk (i.e., in the context of efficacy and safety). The third success is that we have aligned on what DBV believes is a very feasible approach to collecting adhesion data. DBV has initiated study start-up activities and plans to screen the first subject in the second quarter of 2025. Biologic License Application Submission in 1 – 3 Year-Olds There will be two Phase 3 studies in 1 – 3-year-olds using the Viaskin Peanut patch. The data generated from the studies will be used to inform a BLA submission: Twelve months of DBPC efficacy and safety data from the previously completed Phase 3 EPITOPE study (published in the New England Journal of Medicine i n May 2023), and 36 months of open-label extension data. Six months of DBPC data generated in COMFORT Toddlers supplemental safety study. DBV anticipates that the BLA for the Viaskin Peanut patch in toddlers 1 – 3 years-old under the Accelerated Approval program will be submitted in 2H 2026. Investor Conference Call and Webcast DBV management will host an investor conference call and webcast today, Wednesday, December 11 th , at 5:00pm EST, to discuss these regulatory updates. This call is accessible via the below teleconferencing numbers and requesting the DBV Technologies call. United States: +1-877-346-6112 International: +1-848-280-6350 A live webcast of the call will be available on the Investors & Media section of the Company’s website: https://www.dbv-technologies.com/investor-relations/ . A replay of the presentation will also be available on DBV’s website after the event. About DBV Technologies DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary Viaskin® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPITTM), the Viaskin® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age). DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (Ticker: DBVT; CUSIP: 23306J309). For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn . Forward Looking Statements This press release may contain forward-looking statements and estimates, including statements regarding the therapeutic potential of Viaskin® Peanut patch and EPITTM, designs of DBV’s anticipated clinical trials, DBV’s planned regulatory and clinical efforts including timing and results of communications with regulatory agencies, plans and expectations regarding initiation of the confirmatory study, plans and expectations with respect to COMFORT Toddlers and COMFORT Children, plans and expectations with respect to the submission of BLAs to FDA, anticipated support for the BLA submission, DBV’s expectations with respect to the Accelerated Approval pathway and any other actionable regulatory pathway, and the ability of any of DBV’s product candidates, if approved, to improve the lives of patients with food allergies. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, DBV’s product candidates have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and DBV’s ability to successfully execute on its budget discipline measures. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in DBV’s regulatory filings with the French Autorité des Marchés Financiers (“AMF”), DBV’s filings and reports with the U.S. Securities and Exchange Commission (“SEC”), including in DBV’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 7, 2024, and future filings and reports made with the AMF and SEC by DBV. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release. Viaskin is a registered trademark and EPIT is a trademark of DBV Technologies. Investor Contact Katie Matthews DBV Technologies katie.matthews@dbv-technologies.com Media Contact Angela Marcucci DBV Technologies angela.marcucci@dbv-technologies.com Attachment PDF VersionNone

Canadian Prime Minister Justin Trudeau's government on Monday survived a third vote of no confidence in as many months, brought by his main Tory rival. The minority Liberal government got the support of the New Democratic Party (NDP), a small leftist faction once aligned with the ruling Liberals, to defeat the motion 180-152. The text of the proposition echoed NDP leader Jagmeet Singh's own past criticisms of Trudeau since breaking off their partnership in late August, calling him "too weak, too selfish." Neither Singh nor Trudeau were present for the vote. The House of Commons has been deadlocked most of this fall session by an unprecedented two-month filibuster by the Conservatives. But Speaker Greg Fergus, in a rare move, ordered a short break in the deadlock to allow for this and other possible confidence votes, and for lawmakers to vote on a key spending measure. MPs are scheduled to vote Tuesday on the spending package, which includes funds for social services, disaster relief and support for Ukraine. With a 20-point lead in polls, Conservative leader Pierre Poilievre has been itching for an election call since the NDP tore up its coalition agreement with the Liberals. But the NDP and other opposition parties, whose support is needed to bring down the Liberals, have so far refused to side with the Conservatives. Two no-confidence votes brought by the Tories in September and October failed when the NDP and the separatist Bloc Quebecois backed the Liberals. In Canada's Westminster parliamentary system, a ruling party must hold the confidence of the House of Commons, which means maintaining support from a majority of members. The Liberals currently have 153 seats, versus 119 for the Conservatives, 33 for the Bloc Quebecois, and the NDP's 25. Trudeau swept to power in 2015 and has managed to hold on through two elections in 2019 and 2021. amc/bs/bjt

Ragging incident at PSTU hospitalizes 3 students, 7 expelledDo Flying Cars Exist Today? (If So, Who's Making Them?)The Lasting Legacy of Jimmy Carter, Dead at 100

2027: Opposition Lawmakers Raise Alarm Over ‘Plot To Weaken PDP’ With Damagun Stay

AP Trending SummaryBrief at 12:19 p.m. ESTThe Latest: Former President Jimmy Carter is dead at age 100

Previous:
Next: halik jio

czilk dc inc

European Cup News

European Cup video analysis